BridgeBio Announces Positive Preliminary Antitumor Data Across Three Programs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy BBIO?
BridgeBio Oncology Therapeutics announced positive preliminary safety and antitumor data across its three orally bioavailable, differentiated small molecule RAS and PI3Kalpha programs. The data updates include BBO-8520, a direct inhibitor targeting both the ON and OFF states of KRASG12C; BBO-11818, a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states, and BBO-10203, a RAS-PI3Ka breaker with a novel mechanism of action designed to inhibit the physical interaction between RAS and PI3Kalpha. BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer showed a 65% objective response rate and a 66% 6-month progression-free survival, with 83% of patients eligible for 6-month follow-up remaining on treatment for greater than or equal to6 months. BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. BBO-11818 monotherapy demonstrated a confirmed partial response in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation. BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 67.450
Low
85.00
Averages
98.50
High
157.00
Current: 67.450
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Pharma Reports Strong Q1 2026 Earnings and $500M Buyback
- Attruby Sales Growth: BridgeBio Pharma reported $180.6 million in Attruby sales for Q1 2026, reflecting a 24% increase from the previous quarter, indicating strong market performance and positioning the company for continued revenue growth.
- Significant Clinical Data: CEO Neil Kumar highlighted that Attruby demonstrated a 49% reduction in cardiovascular mortality compared to tafamidis in clinical trials, enhancing the product's competitive edge and laying a solid foundation for future sales growth.
- Share Buyback Program: The Board authorized a $500 million share repurchase program aimed at leveraging current market undervaluation to enhance shareholder value while maintaining flexibility for future investments, which is expected to positively impact the stock price.
- Financial Outlook: CFO Thomas Trimarchi indicated that operational losses are expected to stabilize over the next two quarters, with a plan to achieve breakeven by 2027, reflecting the company's confidence in financial management and strategic planning for business expansion.
See More
BridgeBio Pharma Q1 Earnings Report Analysis
- Earnings Performance: BridgeBio Pharma reported a Q1 GAAP EPS of -$0.84, missing expectations by $0.16, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $194.5 million in Q1, representing a 66.8% year-over-year increase and beating market expectations by $15.89 million, reflecting strong demand for its genetic disease products that boosted overall performance.
- Market Reaction: Despite the revenue beat, the decline in GAAP EPS led to stock price volatility, suggesting that investor expectations regarding future profitability may be impacted, necessitating close monitoring of subsequent market developments.
- Strategic Outlook: BridgeBio's continued growth and market share expansion in the genetic disease sector, combined with its robust revenue performance, may support future investment opportunities, particularly in new product development and market promotion.
See More
Brazil Approves Acoramidis for Cardiomyopathy Treatment
- Clinical Trial Results: Acoramidis demonstrated significant efficacy in the ATTRibute-CM Phase 3 study, with a lower incidence of cardiovascular events compared to placebo at one month and a 42% reduction in recurrent cardiovascular hospitalizations at 30 months, highlighting its potential in treating cardiomyopathy.
- Market Authorization Progress: The Brazilian Health Regulatory Agency (ANVISA) has approved Acoramidis (brand name BEYONTTRA) for treating adult patients with cardiomyopathy, making it the first drug globally to receive such approval, significantly expanding treatment options for cardiomyopathy patients.
- Commercialization Partnership: BridgeBio is partnering with Biopas to commercialize BEYONTTRA in Brazil, with efforts expected to begin in the second half of 2026, aiming to quickly provide treatment to cardiomyopathy patients and meet the growing market demand.
- Patient Welfare Improvement: The approval of Acoramidis brings new hope to Brazilian cardiomyopathy patients, significantly improving survival rates and quality of life, reflecting a commitment to addressing this increasingly recognized disease.
See More
BridgeBio to Present ADH1 Study Data at European Congress of Endocrinology
- Clinical Data Presentation: BridgeBio will share additional data from its CALIBRATE Phase 3 study on encaleret for autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology, which is expected to enhance the company's influence in the genetic disease sector.
- Oral Presentation Schedule: The company will conduct two oral presentations on May 12, featuring Dr. Filomena Cetani from the University of Pisa and Dr. Arun Mathew from BridgeBio, covering encaleret's restoration of mineral homeostasis in ADH1 and genetic testing results for non-surgical hypoparathyroidism, likely drawing significant industry attention.
- Poster Presentation Content: During the conference, BridgeBio will also present a poster detailing baseline quality of life measures for adult participants in the CLARIFY disease monitoring study for ADH1 and ADH2, further emphasizing the company's commitment to improving patient quality of life.
- Literature Review Presentation: Additionally, Dr. Arun Mathew will present an e-poster that systematically reviews the epidemiology and clinical management of ADH1, aiming to provide deeper insights into the clinical management of genetic diseases and bolster the company's thought leadership in this area.
See More
BridgeBio to Present New Data at Heart Failure Conference
- Clinical Research Advancement: BridgeBio Pharma will present new data from the ATTRibute-CM study at the 2026 Heart Failure Conference, particularly regarding the impact of Acoramidis on heart failure patients, which is expected to significantly enhance the company's influence in the cardiovascular sector.
- Key Presentation Schedule: Bayer will deliver an oral presentation on May 11 regarding Acoramidis' effects on heart failure outcomes, showcasing its potential to improve patient results, which may attract increased investor interest.
- Drug Approval Information: Acoramidis has received approvals from multiple regulatory agencies, including the FDA and EMA, highlighting its efficacy in treating transthyretin-mediated cardiomyopathy, thereby solidifying BridgeBio's position in the biopharmaceutical industry.
- Safety Data Disclosure: In clinical trials, the incidence of side effects for Acoramidis was relatively low, with diarrhea and upper abdominal pain reported at rates of 11.6% and 5.5%, respectively, indicating good tolerability that may enhance patient confidence in the medication.
See More
Pfizer Settles Patent Disputes with Generic Manufacturers
- Settlement Agreements: Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd. to resolve patent infringement lawsuits over Vyndamax, effectively extending U.S. patent exclusivity to June 1, 2031, thus averting a significant sales drop anticipated in 2029.
- Market Reaction: Morgan Stanley noted that the settlement is at the lower end of investor expectations, leading to a slight decline in Pfizer's shares, while rival BridgeBio's stock fell 6%, indicating cautious market sentiment towards Pfizer's resolution.
- Revenue Stability Outlook: Pfizer expects Vyndamax revenues to remain relatively stable from 2028 through mid-2031 due to the settlement preventing earlier generic entry, thereby preserving its 75% prescription volume share in the ATTR-CM market.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around BridgeBio stock surged from 'bullish' to 'extremely bullish', while Pfizer's sentiment remained neutral, reflecting investors' sensitivity to market developments.
See More
BridgeBio Pharma Reports Strong Q1 2026 Earnings and $500M Buyback
- Attruby Sales Growth: BridgeBio Pharma reported $180.6 million in Attruby sales for Q1 2026, reflecting a 24% increase from the previous quarter, indicating strong market performance and positioning the company for continued revenue growth.
- Significant Clinical Data: CEO Neil Kumar highlighted that Attruby demonstrated a 49% reduction in cardiovascular mortality compared to tafamidis in clinical trials, enhancing the product's competitive edge and laying a solid foundation for future sales growth.
- Share Buyback Program: The Board authorized a $500 million share repurchase program aimed at leveraging current market undervaluation to enhance shareholder value while maintaining flexibility for future investments, which is expected to positively impact the stock price.
- Financial Outlook: CFO Thomas Trimarchi indicated that operational losses are expected to stabilize over the next two quarters, with a plan to achieve breakeven by 2027, reflecting the company's confidence in financial management and strategic planning for business expansion.
See More
BridgeBio Pharma Q1 Earnings Report Analysis
- Earnings Performance: BridgeBio Pharma reported a Q1 GAAP EPS of -$0.84, missing expectations by $0.16, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $194.5 million in Q1, representing a 66.8% year-over-year increase and beating market expectations by $15.89 million, reflecting strong demand for its genetic disease products that boosted overall performance.
- Market Reaction: Despite the revenue beat, the decline in GAAP EPS led to stock price volatility, suggesting that investor expectations regarding future profitability may be impacted, necessitating close monitoring of subsequent market developments.
- Strategic Outlook: BridgeBio's continued growth and market share expansion in the genetic disease sector, combined with its robust revenue performance, may support future investment opportunities, particularly in new product development and market promotion.
See More
Brazil Approves Acoramidis for Cardiomyopathy Treatment
- Clinical Trial Results: Acoramidis demonstrated significant efficacy in the ATTRibute-CM Phase 3 study, with a lower incidence of cardiovascular events compared to placebo at one month and a 42% reduction in recurrent cardiovascular hospitalizations at 30 months, highlighting its potential in treating cardiomyopathy.
- Market Authorization Progress: The Brazilian Health Regulatory Agency (ANVISA) has approved Acoramidis (brand name BEYONTTRA) for treating adult patients with cardiomyopathy, making it the first drug globally to receive such approval, significantly expanding treatment options for cardiomyopathy patients.
- Commercialization Partnership: BridgeBio is partnering with Biopas to commercialize BEYONTTRA in Brazil, with efforts expected to begin in the second half of 2026, aiming to quickly provide treatment to cardiomyopathy patients and meet the growing market demand.
- Patient Welfare Improvement: The approval of Acoramidis brings new hope to Brazilian cardiomyopathy patients, significantly improving survival rates and quality of life, reflecting a commitment to addressing this increasingly recognized disease.
See More
BridgeBio to Present ADH1 Study Data at European Congress of Endocrinology
- Clinical Data Presentation: BridgeBio will share additional data from its CALIBRATE Phase 3 study on encaleret for autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology, which is expected to enhance the company's influence in the genetic disease sector.
- Oral Presentation Schedule: The company will conduct two oral presentations on May 12, featuring Dr. Filomena Cetani from the University of Pisa and Dr. Arun Mathew from BridgeBio, covering encaleret's restoration of mineral homeostasis in ADH1 and genetic testing results for non-surgical hypoparathyroidism, likely drawing significant industry attention.
- Poster Presentation Content: During the conference, BridgeBio will also present a poster detailing baseline quality of life measures for adult participants in the CLARIFY disease monitoring study for ADH1 and ADH2, further emphasizing the company's commitment to improving patient quality of life.
- Literature Review Presentation: Additionally, Dr. Arun Mathew will present an e-poster that systematically reviews the epidemiology and clinical management of ADH1, aiming to provide deeper insights into the clinical management of genetic diseases and bolster the company's thought leadership in this area.
See More
BridgeBio to Present New Data at Heart Failure Conference
- Clinical Research Advancement: BridgeBio Pharma will present new data from the ATTRibute-CM study at the 2026 Heart Failure Conference, particularly regarding the impact of Acoramidis on heart failure patients, which is expected to significantly enhance the company's influence in the cardiovascular sector.
- Key Presentation Schedule: Bayer will deliver an oral presentation on May 11 regarding Acoramidis' effects on heart failure outcomes, showcasing its potential to improve patient results, which may attract increased investor interest.
- Drug Approval Information: Acoramidis has received approvals from multiple regulatory agencies, including the FDA and EMA, highlighting its efficacy in treating transthyretin-mediated cardiomyopathy, thereby solidifying BridgeBio's position in the biopharmaceutical industry.
- Safety Data Disclosure: In clinical trials, the incidence of side effects for Acoramidis was relatively low, with diarrhea and upper abdominal pain reported at rates of 11.6% and 5.5%, respectively, indicating good tolerability that may enhance patient confidence in the medication.
See More
Pfizer Settles Patent Disputes with Generic Manufacturers
- Settlement Agreements: Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd. to resolve patent infringement lawsuits over Vyndamax, effectively extending U.S. patent exclusivity to June 1, 2031, thus averting a significant sales drop anticipated in 2029.
- Market Reaction: Morgan Stanley noted that the settlement is at the lower end of investor expectations, leading to a slight decline in Pfizer's shares, while rival BridgeBio's stock fell 6%, indicating cautious market sentiment towards Pfizer's resolution.
- Revenue Stability Outlook: Pfizer expects Vyndamax revenues to remain relatively stable from 2028 through mid-2031 due to the settlement preventing earlier generic entry, thereby preserving its 75% prescription volume share in the ATTR-CM market.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around BridgeBio stock surged from 'bullish' to 'extremely bullish', while Pfizer's sentiment remained neutral, reflecting investors' sensitivity to market developments.
See More
